Aurobindo Pharma Q1 Review - Product Development, Capacity Build-Up Underway For Niche Products: Motilal Oswal

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Aurobindo Pharma Ltd. delivered in-line quarter at operational level. The company posted strong YoY growth in the anti-retroviral/rest of world segments and reported growth in the U.S. segment despite intensified competitive environment.

We cut our earnings per share estimates by 9%/3% for FY23/FY24, respectively, to factor in:

1. moderation in the Europe outlook,

2. higher operational cost and

3. lower other income.

We remain positive on Aurobindo Pharma aided by its:

1. strong abbreviated new drug application pipeline comprising limited competition products in oncology, biosimilars, topicals, transdermal patches, etc. and

2. ongoing efforts to improve the profitability of the Europe business.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.